# Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

> **NCT02842021** · PHASE2 · TERMINATED · sponsor: **Sol-Gel Technologies, Ltd.** · enrollment: 283 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** S2G6T-1
- **DRUG:** S2G6T-2
- **DRUG:** S2G6T-3
- **DRUG:** S2G6T-4

## Key facts

- **NCT ID:** NCT02842021
- **Lead sponsor:** Sol-Gel Technologies, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 283 (ACTUAL)
- **Why stopped:** Failed to meet success criteria
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842021, "Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02842021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*